Effect of Iron and Folic Acid tablet and capsule formulation on drug compliance

Effect of Iron and Folic Acid tablet versus capsule formulation on treatment adherence and iron status among pregnant women: a randomized control trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/04/013361

Enrollment

112

Registered

2018-04-19

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Capsule Ferrous fumarate: Ferrous fumarate capsules, which contain 100 mg of elemental iron Prophylaxis - 1 Cap OD Anemic - 1 Cap BD To be given for 100 Days Route - Oral Control Inter

Eligibility

Inclusion criteria

Inclusion criteria: • Pregnant women who have not been booked earlier for the current pregnancy and are more than 12 weeks of gestation.

Exclusion criteria

Exclusion criteria: • Refusal to provide written consent • Hematological disorder (except Anemia) • Severe anemia requiring blood transfusion ( • Already taking IFA preparations for the current pregnancy

Design outcomes

Primary

Measure	Time frame
1. Adherence to tablet and capsule formulation of IFA (pill count and recall method) 2. Difference between mean hemoglobin level change after 100 days of IFA (Capsule or Tablet) consumption Timepoint: At the End of the study (August 2014)	—

Secondary

Measure	Time frame
1. Association of IFA adherence with various socio-demographic and other factors 2. Prevalence of various side effects of IFA preparationTimepoint: At the End of the study (August 2014)	—

Countries

India

Contacts

Public ContactDr Rahul Srivastava

AIIMS, New Delhi

drsrivastava.rahul@gmail.com

Outcome results